Cogent Biosciences Valuation Multiples

Cogent Biosciences Overview

About Cogent Biosciences

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Founded

2014

HQ

Employees

258

Website

cogentbio.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $5M

EBITDA: ($313M)

EV

$6B

Valuation Multiples

Multiples.vc

Start free trial

Cogent Biosciences Financials

Cogent Biosciences reported last 12-month revenue of $5M and negative EBITDA of ($313M).

In the same LTM period, Cogent Biosciences generated $4M in gross profit, ($313M) in EBITDA losses, and had net loss of ($340M).

Cogent Biosciences P&L

In the most recent fiscal year, Cogent Biosciences reported revenue of — and EBITDA of ($286M).

Cogent Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

Cogent Biosciences Stock Performance

Cogent Biosciences has current market cap of $6B, and enterprise value of $6B.

Cogent Biosciences' stock price is $38.85.

Cogent Biosciences Valuation Multiples

Cogent Biosciences trades at 1211.4x EV/Revenue multiple, and (18.3x) EV/EBITDA.

Cogent Biosciences Financial Valuation Multiples

As of April 8, 2026, Cogent Biosciences has market cap of $6B and EV of $6B.

Equity research analysts estimate Cogent Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Cogent Biosciences has a P/E ratio of (18.5x).

Cogent Biosciences Margins & Growth Rates

Cogent Biosciences' revenue in the last 12 month grew by 2194%.

Cogent Biosciences' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.3M for the same period.

Cogent Biosciences Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Cogent Biosciences M&A Activity

Cogent Biosciences acquired XXX companies to date.

Last acquisition by Cogent Biosciences was on XXXXXXXX, XXXXX. Cogent Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Cogent Biosciences Investment Activity

Cogent Biosciences invested in XXX companies to date.

Cogent Biosciences made its latest investment on XXXXXXXX, XXXXX. Cogent Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).